newsfilter
← Latest News
GlobeNewswire·

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24